- Trial phase
- Phase 1
- Time to market
- BG-C477 is in Phase 1 clinical development with no pivotal trial yet initiated. Even with an accelerated path, a potential approval would be several years away, likely 2029 or later.
- Why 3/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The Phase 1a data was just presented at ESMO in October 2026. The Phase 1b expansion is ongoing with no specific topline readout date announced. BG-C477 is one of many early-stage programs at a large, multi-asset oncology company (BeOne has 35+ clinical and commercial assets), so even positive data would have limited stock impact. ImpactScore is 3 per the rubric: an early-stage drug with no near-term binary catalyst at a diversified company.
The next meaningful catalyst for BG-C477 will be further Phase 1b data, potentially at a major medical congress in 2027 (e.g., ASCO or ESMO), or an announcement of a Phase 2/pivotal trial initiation. Investors should watch for whether BeOne discloses a registrational path and timeline. The competitive landscape is also key: Merck KGaA's Precem-TcT is already in Phase 3, so BG-C477 needs to show differentiation in efficacy, safety, or target indications to carve out a commercial niche.
Price Chart
Executive Summary
BG-C477 is an investigational antibody-drug conjugate (ADC) targeting CEACAM5 (CEA), developed by BeOne Medicines Ltd. (ticker: ONC, formerly BeiGene). It is in Phase 1a/b clinical development for advanced solid tumors. Initial Phase 1a data presented at ESMO 2026 showed a 60% confirmed response rate in CEA-high NSCLC patients with a favorable safety profile. However, the drug is early-stage (Phase 1), faces competition from Merck KGaA's Precem-TcT which is already in Phase 3, and represents a small part of BeOne's broad pipeline. No near-term binary catalyst is scheduled.
How It Works
BG-C477 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: one part is an antibody that binds specifically to a protein called CEA (or CEACAM5) found at high levels on many cancer cells, and the other part is a chemotherapy payload (a topoisomerase 1 inhibitor) that kills the cell once delivered inside. The drug-to-antibody ratio is 8, meaning each antibody carries eight drug molecules.
Trial Status
BG-C477 is being studied in a global, multicenter, open-label Phase 1a/b first-in-human trial (NCT06596473) in patients with advanced solid tumors. The Phase 1a dose-escalation portion in non-small cell lung cancer (NSCLC) has completed enrollment. Initial results were presented at the ESMO 2026 Congress (October 23-27, 2026, Madrid). The Phase 1b dose-expansion portion is ongoing, evaluating BG-C477 alone and in combination with other anticancer agents including tislelizumab. The trial is expected to complete by December 31, 2027, with 310 patients planned across 54 sites globally.
The Two-Sided Case
Upcoming Catalysts
- Further Phase 1b dose-expansion data readouts (no specific date announced)
- Potential initiation of a Phase 2 or pivotal study (timing not yet disclosed)
- Additional data at future medical congresses (e.g., ASCO 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BeOne Medicines Ltd. 8-K ONC ·Originating report